{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:49:24Z","timestamp":1791679764866,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.anai.2024.11.004","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T21:15:01Z","timestamp":1731618901000},"page":"341-350.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States"],"prefix":"10.1016","volume":"134","author":[{"given":"Sameer K.","family":"Mathur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"MacKnight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Urosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijita","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2024.11.004_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.627776","article-title":"Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology","volume":"8","author":"Fagni","year":"2021","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.anai.2024.11.004_bib0002","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.41982","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.anai.2024.11.004_bib0003","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.autrev.2014.12.004","article-title":"Churg\u2013Strauss syndrome","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.anai.2024.11.004_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/RHU.0000000000001198","article-title":"Prevalence of eosinophilic granulomatosis with polyangiitis and associated health care utilization among patients with concomitant asthma in US commercial claims database","volume":"27","author":"Gokhale","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.anai.2024.11.004_bib0005","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1007\/s10067-021-05783-8","article-title":"Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis","volume":"40","author":"Jakes","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.anai.2024.11.004_bib0006","first-page":"1249","article-title":"Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States","volume":"27","author":"Bell","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"10.1016\/j.anai.2024.11.004_bib0007","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.anai.2024.11.004_bib0008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.anai.2024.11.004_bib0009","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.anai.2024.11.004_bib0010","article-title":"Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases","volume":"14","author":"Del Pozo","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.11.004_bib0011","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials","volume":"54","author":"Robson","year":"2015","journal-title":"Rheumatol (Oxf Engl)"},{"key":"10.1016\/j.anai.2024.11.004_bib0012","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.anai.2024.11.004_bib0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"10.1016\/j.anai.2024.11.004_bib0014","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2024.11.004_bib0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.anai.2024.11.004_bib0016","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13075-023-03097-5","article-title":"Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan","volume":"25","author":"Yamane","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.anai.2024.11.004_bib0017","unstructured":"Food and Drug Administration. Nucala prescribing information. Accessed July 23, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125526Orig1s021,761122Orig1s011Corrected_lbl.pdf"},{"key":"10.1016\/j.anai.2024.11.004_bib0018","unstructured":"Food and Drug Administration. Fasenra prescribing information. Accessed October 18, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761070s021lbl.pdf."},{"issue":"12","key":"10.1016\/j.anai.2024.11.004_bib0019","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/ard-2022-222776","article-title":"Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study","volume":"81","author":"Bettiol","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.anai.2024.11.004_bib0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.anai.2024.11.004_bib0021","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12931-021-01775-z","article-title":"Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series","volume":"22","author":"Detoraki","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2024.11.004_bib0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clicom.2022.01.002","article-title":"Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"2","author":"Ramirez","year":"2022","journal-title":"Clin Immunol Commun"},{"issue":"1","key":"10.1016\/j.anai.2024.11.004_bib0023","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-021-02462-6","article-title":"Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis","volume":"23","author":"Ueno","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.anai.2024.11.004_bib0024","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3899\/jrheum.150479","article-title":"Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States","volume":"42","author":"Raimundo","year":"2015","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.anai.2024.11.004_bib0025","first-page":"e42241","article-title":"Retrospective analysis of the burden of illness of eosinophilic granulomatosis with polyangiitis (EGPA) versus asthma in commercially insured US patients","volume":"15","author":"Bell","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.anai.2024.11.004_bib0026","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.anai.2024.11.004_bib0027","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.anai.2024.11.004_bib0028","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/RHU.0000000000002033","article-title":"Characteristics and disease burden of patients with eosinophilic granulomatosis with polyangiitis initiating mepolizumab in the United States","volume":"29","author":"Silver","year":"2023","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.anai.2024.11.004_bib0029","first-page":"36","article-title":"Biologics for eosinophilic granulomatosis with polyangiitis","volume":"23","author":"Caminati","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2024.11.004_bib0030","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624016612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624016612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T04:24:33Z","timestamp":1740975873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624016612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1081120624016612"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.11.004","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}